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Abstract Interleukin-5 (IL-5) plays a crucial role in the
proliferation, differentiation and activation of eosinophils. The
IL-5 receptor is composed of an IL-5-specific K subunit, which is
expressed by eosinophils and basophils, and a Lc-subunit shared
with the receptors for IL-3 and GM-CSF. We identified an AP-1
element which is important for IL-5RK promoter activity in
eosinophilic HL60 cells. The AP-1 site and the previously
identified EOS1 site cooperate, since single mutation of either of
the sites decreased promoter activity. We show that the AP-1 site
of the IL-5RK promoter binds multiple proteins, including cJun,
CREB, and CREM.
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1. Introduction
Cytokines such as interleukin-3 (IL-3) and GM-CSF are
involved in the early di¡erentiation of multiple lineages,
whereas IL-5 is selectively controlling the terminal di¡erentia-
tion of eosinophils and basophils [1^3]. In humans the IL-5
receptor (IL-5R) consists of an K and a L chain, both mem-
bers of the class I cytokine receptor family. The K chain (IL-
5RK) is exclusively expressed on eosinophils and basophils
and binds IL-5 with moderate a⁄nity [4^7]. The L chain is
shared with the receptors for IL-3 and GM-CSF and is widely
expressed in various hematopoietic lineages [8]. The L chain
does not bind IL-5 by itself, but associates with the IL-5RK
subunit to form a high a⁄nity receptor [5,9,10].
Expression of the IL-5RK gene is critical to the entry of
multipotential myeloid progenitors into an eosinophil/baso-
phil developmental program. The gene encoding the human
IL-5RK chain is located on chromosome 3. Recently the 5P
upstream region of this gene was isolated, which appears to be
highly active in eosinophilic cell lines [11]. The promoter re-
gion contains multiple consensus sites for known hemato-
poietic transcription factors, including GATA, PU1, C/EBP,
and AP-1. Sun et al. [12] identi¢ed a unique enhancer-like cis
element (EOS1) that is necessary and su⁄cient for promoter
activity and binds an unknown transcription factor. In this
study we have studied the involvement of an AP-1 site in the
regulation of the IL-5RK gene. The AP-1 family is a set of
sequence speci¢c transcription factors, including the Jun, Fos,
and activating transcription factor (ATF, including CREB
and CREM) families, which form a variety of hetero- and
homodimers [13,14]. Interestingly, AP-1 family members are
known to be involved in the regulation of myeloid di¡erentia-
tion [15^17].
In this study we demonstrate that, besides the EOS1 site,
the AP-1 element of the IL-5RK promoter located between
3440 and 3432 is also involved in the regulation of IL-5RK
chain expression and acts synergistically with the EOS1 site.
2. Materials and methods
2.1. Cell culture, reagents, and antibodies
Promyelocytic leukemia-HL60 cells were cultured in RPMI 1640
(Life Technologies, Breda, The Netherlands) supplemented with 8%
fetal calf serum (FCS, Hyclone), 100 U/ml penicillin (Life Technolo-
gies), 100 Wg/ml streptomycin (Life Technologies) and 50 WM L-mer-
captoethanol. HL60 7.7 cells were generated by culturing HL60 cells
for two months at pH 7.7 in RPMI containing 25 mmol/l N-[2-hy-
droxyethyl]piperazine-NP-3-propane-sulfonic acid (EPPS; Sigma, St.
Louis, MO, USA). To further di¡erentiate HL60 7.7 cells butyric
acid (0.5 mmol/l ; Sigma) was added up to 6 days. Polyclonal rabbit
antibody against cJun was obtained from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). The antibodies against CREB and CREM
were described previously [18].
2.2. Synthetic oligonucleotides and plasmid construction
The following oligonucleotides were used in this study (only the
upper strands are shown): AP-1 (5P-AGCTTAAATCATGTGT-
CAGTGTTGA-3P), AP-1 mutant (5P-AGCTTAAATCATGGGCCC-
GTGTTGA-3P), Col-TRE (5P-GATCTATCTGAGTCAGCAG-3P),
c-jun TRE (5P-GATCTATCTGACATCAGCAG-3P), and SP1
(5P-AGCTTGGGGCGGGGCT-3P). A human genomic DNA library
(V Fix II, Stratagene) was screened using a random primed IL-5RK
probe (provided by Dr. B. Allet, Glaxo Institute). Secondary and
tertiary screening was performed using an oligo corresponding to
most of the ¢rst exon [6]. Isolated DNA fragments were cloned into
the KpnI-NotI sites of the pBKS II phagemid (Stratagene). Fragments
of the IL-5RK upstream sequence were generated using the polymer-
ase chain reaction with primers containing HindIII and PstI sites for
sense and antisense sequences, respectively, and ligated into the pCAT
basic vector (Promega). Site-directed mutagenesis was performed as
described by Kunkel [19].
2.3. Electro mobility shift assay
Nuclear extracts were prepared from the di¡erent HL60 sublines
following a previously described procedure [20]. Oligonucleotides were
labeled by ¢lling in the cohesive with [K-32P]dCTP using Klenow frag-
ment of DNA polymerase I (Life Technologies). Gel retardation as-
says were carried out according to published procedures with slight
modi¢cations [21]. Brie£y, nuclear extracts were incubated in a total
volume of 20 Wl, containing 10 mM HEPES-KOH, pH 7.9, 50 mM
KCl, 5 mM MgCl2, 1 mM EDTA, 10% (v/v) glycerol, 5 mM DDT, 20
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Wg bovine serum albumin (BSA), 2 Wg poly(dI-dC) (Pharmacia Bio-
tech.) and 1 ng of a [K-32P]-labeled AP-1 oligonucleotide for 20 min at
room temperature. In competition experiments, indicated molar excess
of unlabeled oligonucleotide was added simultaneously with the
[K-32P]-labeled oligonucleotide. Antibodies were incubated 30 min
on ice prior to the addition of [K-32P]-labeled oligonucleotide. Pro-
tein-DNA complexes were then separated on 5% non-denaturing
polyacrylamide gels and visualized by autoradiography.
2.4. Transient transfection and CAT assay
HL60 cells were transfected by electroporation (280 V, 960 WF).
Transfected cells were harvested for CAT assays after 48 h. Cells
were lyzed by repeated freeze thawing in 250 mM Tris, pH 7.4, 25
mM EDTA. Cellular extract was incubated in a total volume of 200 Wl
200 mM Tris, pH 7.4, 4% glycerol, 0.5 mg/ml butyryl CoA and 0.05
WCi [14C]chloramphenicol for 2 h at 37‡C. Reaction products were
then extracted using 400 Wl xylene/pristane (1:2), and the percentage
of acetylated products was then determined using liquid scintillation
counting. A CMV-lacZ construct was co-transfected to correct for
di¡erences in transfection e⁄ciency.
2.5. RNA isolation and Northern blotting
For Northern blotting, RNA (20 Wg) was electrophoretically sepa-
rated on 0.8% agarose gel and transferred to Hybond (Amersham,
Arlington Heights, IL, USA). Blots were hybridized with randomly
32P-labeled IL-5RK, c-jun, or GAPDH fragments overnight at 42‡C in
hybridization bu¡er, washed, and exposed to ¢lm as described previ-
ously [22].
3. Results
IL-5RK expression was previously shown to be upregulated
during eosinophilic di¡erentiation of HL60 clone 15 cells
[10,23]. To investigate whether in HL60 cells di¡erentiated
at pH 7.7 IL-5R expression is also responsive to BA, RNA
was isolated from HL60 7.7 cells treated for various periods
with BA. Fig. 1 shows an increase in the expression of the IL-
5R by BA treatment after 3 days. Reprobing the blot with a
GAPDH probe shows that equal amounts of RNA were
loaded in each lane (Fig. 1). These results demonstrate that
HL60 7.7 cells are suitable for studying the regulation of the
IL-5RK promoter.
Previously it was shown that the EOS1 enhancer located at
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Fig. 1. The expression of the IL-5RK chain is upregulated during
the di¡erentiation of HL60 7.7 cells. RNA was isolated from HL60
7.7 cells treated for various times with butyric acid (BA, 0.5 mM)
and analyzed for expression of the IL-5RK chain gene, c-jun and
GAPDH. Eosinophilic di¡erentiation of HL60 7.7 cells is clearly ac-
companied by an increase in expression of the IL-5RK chain and c-
jun genes.
Fig. 2. An AP-1 site in the promoter of IL-5RK chain is involved in its activity in eosinophilic HL60 cells. A: HL60 7.7 cells treated for three
days with BA were transfected with various progressive 5P deletion constructs of the IL-5RK chain promoter. Two days after transfection, CAT
assays were performed to determine the regions of the IL-5RK chain promoter involved in its eosinophilic activity. B: IL-5RK chain promoter
constructs with mutations in either the EOS1 site or the AP-1 site were analyzed as described in A. It is clear that both the EOS1 site and the
AP-1 site are necessary for full promoter activity.
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3430 to 3422 was necessary for the activity of the IL-5RK
chain promoter in HL60 clone 15 cells [12]. We transfected
HL60 7.7BA cells with a number of 5P deletion constructs to
determine the IL-5RK chain promoter region essential for
activity in eosinophilic cells. Fig. 2A shows that deletion of
a promoter region between 3467 and 3408 results in a com-
plete loss of promoter activity in BA-di¡erentiated HL60 7.7
cells. This region contains the previously identi¢ed EOS1 en-
hancer [12]. However, sequence analysis of the promoter of
the IL-5RK chain revealed the presence of a potential AP-1
binding site (5P-ATGTGTCAG-3P) next to the previously
identi¢ed EOS1 site [12]. Since members of the AP-1 family
are known as positive regulators of myeloid di¡erentiation
[15^17], we determined whether the AP-1 site plays a role in
promoter activity. Therefore the AP-1 site was mutated in the
3467 construct and promoter activity was determined in
HL60 7.7BA cells. Mutation of this EOS1 site resulted in a
dropped promoter activity, comparable to background, as
shown previously [12]. Surprisingly, single mutation of the
AP-1 site resulted also in a complete loss of promoter activity
of the construct (Fig. 2B). The activity of the construct having
both the EOS1 and the AP-1 site mutated was comparable
with background level (Fig. 2B). These results show that the
EOS1 and the AP-1 site are both involved in the regulation of
the IL-5RK gene.
To investigate the nature of the proteins binding to the
putative AP-1 binding site in the IL-5RK gene promoter, gel
mobility shift assays with a radio-labeled double stranded
oligonucleotide containing this AP-1 site were performed.
Fig. 3A shows a complex that binds to the AP-1 element in
HL60 7.7BA cells. The speci¢city of the protein-complex
binding to the AP-1 probe was demonstrated by competition
with a 10^100-fold molar excess of the unlabeled oligonucleo-
tide (Fig. 3A). By contrast, oligonucleotides containing a mu-
tated AP-1 site or a control SP-1 binding site were not able to
compete for binding (Fig. 3A). To study the properties of the
AP-1 element, we examined the competition of the formation
of this complex with known AP-1 sites. Oligonucleotides con-
taining a TPA (12-O-tetradecanoylphorbol-13-acetate) re-
sponse element (TRE) from the collagenase promoter, or
from the c-jun promoter were able to block the binding to
the AP-1 site of the IL-5RK promoter, although to somewhat
di¡erent extents (Fig. 3A). In addition, the binding could also
blocked by an oligo containing a cAMP response element
(CRE) (data not shown). These results indicate that these sites
bind proteins or protein complexes that are also able to bind
the AP-1 site of the IL-5RK promoter.
To further characterize the protein complex binding to the
AP-1 binding site within the IL-5RK promoter, nuclear ex-
tracts of HL60 7.7BA cells were incubated with antibodies
against di¡erent AP-1 family members and additional tran-
scription factors prior to detection of DNA-protein interac-
tions by gel mobility shift assay. The antibodies against
CREB, CREM and cJun induced a supershift of the labeled
DNA probe (Fig. 3C), indicating that their respective antigens
participate in the formation of the complex bound to the AP-
1 site of the IL-5RK promoter. In contrast, there was no
supershift with antibodies against JunD, c-fos, and ATF3
(data not shown).
While CREB and CREM are ubiquitously expressed pro-
teins, the expression of cJun is tightly regulated. Therefore, we
analyzed the expression of cJun mRNA in HL60 7.7 cells after
addition of BA which coincides with the increase in expression
of the IL-5RK gene (Fig. 1). There is a remarkable increase in
the expression of cJun mRNA after three to four days of
addition of BA. Treatment of HL60 7.7 cells with retinoic
acid, an inducer of neutrophilic HL60 di¡erentiation, did
not induce cJun mRNA expression (data not shown). These
results indicate that cJun expression is upregulated during
eosinophilic di¡erentiation of the HL60 7.7 cell line, and is
likely to play an important role in regulating IL-5RK expres-
sion.
4. Discussion
It has been previously reported that the activity of the IL-
5RK promoter is regulated by the EOS-1 element which binds
an unknown myeloid speci¢c factor [12]. As shown in this
study, expression of the IL-5RK gene is also regulated by
the AP-1 element of the promoter. Since single mutation of
one of the sites inhibited promoter activity, these results in-
dicate that the proteins binding to the AP-1 site and EOS1 site
cooperate. This suggests that an eosinophil speci¢c transcrip-
tion factor cooperates with a general transcription factor and
together regulate the expression of the IL-5RK chain.
Gel retardation assays showed the binding of a nuclear
protein complex to the AP-1 oligonucleotide. This binding
could be inhibited with the unlabeled self-oligonucleotide
and also with other known AP-1 elements, such as a CRE
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Fig. 3. The AP-1 site in the IL-5RK chain promoter binds multiple
AP-1 family proteins. A: Nuclear extracts isolated from HL60 7.7
cells treated for 4 days with BA were tested for proteins binding to
the AP-1 site from the IL-5RK chain promoter in a gel shift experi-
ment. The speci¢city of the complex was determined by competition
with 10^100-fold molar excess of unlabeled self-oligonucleotide of
mutated AP-1 site, SP-1 site, collagenase TRE or c-jun TRE. B:
Mutation of the AP-1 site completely inhibits protein binding to the
oligonucleotide, as shown by gel shift analysis using the wild-type
or mutated AP-1 site from the IL-5RK chain promoter as a probe.
C: Supershift analysis with antibodies to c-jun, CREB, CREM
show the binding of these proteins to the AP-1 site from the IL-
5RK chain promoter in HL60 7.7BA cells. An antibody to STAT3
was used as a negative control.
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site and TRE sites from the collagenase or the c-jun promoter.
These results suggest that the AP-1 site of the IL-5RK pro-
moter is most related to the CRE which can bind dimers of
the ATF family and TRE sites which binds cJun. We showed
with supershift analysis the presence of the proteins cJun,
CREB, and CREM in the shifted complex. There was not a
supershift with antibodies against other AP-1 family members
such as JunD, c-Fos, and ATF3. This suggests a role for cJun,
CREB, and CREM in the binding complexes of the AP-1 site.
The expression of cJun mRNA is increased during di¡erentia-
tion of HL60 cells, indicating that cJun might play a role in
eosinophil speci¢c gene transcription. It may be that during
eosinophilic di¡erentiation the expression of the IL-5RK chain
gene is regulated by di¡erent protein complexes of AP-1 fam-
ily members. Interestingly, others also found the involvement
of AP-1 family members in the di¡erentiation of myeloid cells
[15^17].
Recently, a second promoter region for the IL-5RK gene
was identi¢ed [24], located within the ¢rst intron. This second
promoter is only active in eosinophilic HL60-C15 cells and the
nuclear factor binding to this promoter is also only present in
these cells. The existence of another promoter site of the IL-
5RK chain suggests that the transcription of IL-5RK is under
the control of multiple promoters, like other genes such as
insulin-like growth factor and colony stimulating factor 1
[25,26]. It is possible that, during eosinophil maturation, an
alternative use of the promoters may determine stage-speci¢c
expression of the IL-5RK gene.
The production of eosinophils from bone marrow progen-
itors as well as the priming, activation, and enhanced survival
of mature eosinophils is regulated by IL-5 [1^4]. Understand-
ing the regulation of the IL-5RK gene orders an opportunity
in controlling the development, di¡erentiation, activation, and
prolonged survival of the mature eosinophils. We have shown
the contribution of the AP-1 site to this regulation. Further
experiments are needed to resolve the precise roles of the
EOS1 and AP-1 elements and binding proteins.
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